Hematological malignancies in connective tissue diseases
暂无分享,去创建一个
A. Taher | I. Uthman | M. A. Noureldine | M. H. Noureldine | H. Noureldine | W. Nour-Eldine | M. Hodroj | M. Noureldine | M. H. Hodroj
[1] Y. Shoenfeld,et al. Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival , 2019, Oncoimmunology.
[2] A. Alunno,et al. One year in review 2018: pathogenesis of rheumatoid arthritis. , 2018, Clinical and experimental rheumatology.
[3] J. Gómez-Reino,et al. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. , 2017, Seminars in arthritis and rheumatism.
[4] M. Ehrenfeld,et al. Cancer and autoimmune diseases. , 2017, Autoimmunity reviews.
[5] C. Vacchi,et al. Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature , 2017, Case reports in rheumatology.
[6] A. Selva-O'Callaghan,et al. Novel risk factors related to cancer in scleroderma. , 2017, Autoimmunity reviews.
[7] A. López-Guillermo,et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome , 2017, Journal of Hematology & Oncology.
[8] C. Brunet,et al. Rheumatologic Manifestations of Hematologic Neoplasms. , 2017, Current rheumatology reviews.
[9] S. Tiosano,et al. Coexistent malignant conditions in rheumatoid arthritis – A population‐based cross‐sectional study , 2017, International journal of clinical practice.
[10] S. Tiosano,et al. Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study , 2017, Immunologic Research.
[11] J. Mosak,et al. Systemic Sclerosis and Malignancy: A Review of Current Data , 2016, Journal of clinical medicine research.
[12] L. See,et al. Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases , 2016, Medicine.
[13] F. Yıldız,et al. Risk factors for malignancy in systemic sclerosis patients , 2016, Clinical Rheumatology.
[14] X. Mariette,et al. Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome , 2016, Arthritis & rheumatology.
[15] A. Yoshizaki. B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets , 2016, The Journal of dermatology.
[16] Ami A. Shah,et al. Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening , 2015, Current opinion in rheumatology.
[17] S. Bernatsky,et al. Malignancies in systemic lupus erythematosus: a 2015 update , 2015, Current opinion in rheumatology.
[18] M. Hochberg,et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis , 2015, Arthritis Research & Therapy.
[19] L. Teuwen,et al. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study , 2015, Clinical Rheumatology.
[20] C. Chizzolini,et al. The role of the acquired immune response in systemic sclerosis , 2015, Seminars in Immunopathology.
[21] A. Tzioufas,et al. Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome. , 2015, Autoimmunity reviews.
[22] D. Kanduc,et al. EBV-Associated Cancer and Autoimmunity: Searching for Therapies , 2015, Vaccines.
[23] Raveendhara R. Bannuru,et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .
[24] B. Houston,et al. T cell ALL presenting as seropositive rheumatoid arthritis: case report and review of the literature on seropositive paraneoplastic arthritis , 2015, Clinical Rheumatology.
[25] M. Koutsilieris,et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. , 2014, Journal of autoimmunity.
[26] A. Manfredi,et al. Radiological thymus alterations in systemic sclerosis: our experience and a review of the literature. , 2014, Rheumatology.
[27] Y. Zu,et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Ami A. Shah,et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma , 2014, Arthritis Research & Therapy.
[29] Yuchen Jiao,et al. Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer , 2014, Science.
[30] D. Gladman,et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment , 2012, Annals of the rheumatic diseases.
[31] J. Andreu,et al. Identification of lymphoma predictors in patients with primary Sjögren’s syndrome: a systematic literature review and meta-analysis , 2014, Rheumatology International.
[32] M. Colombo,et al. Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. , 2014, Cancer Discovery.
[33] K. Bogunia-Kubik,et al. [Tumors in rheumatic diseases]. , 2013, Postepy higieny i medycyny doswiadczalnej.
[34] X. Mariette,et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. , 2013, Arthritis and rheumatism.
[35] D. Gladman,et al. Epigenetics and lupus , 2012, Arthritis Research & Therapy.
[36] G. Houen,et al. Epstein-Barr Virus in Systemic Autoimmune Diseases , 2013, Clinical & developmental immunology.
[37] D. Sugiyama,et al. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. , 2013, Arthritis and rheumatism.
[38] K. Ohshima,et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein–Barr virus, and clonality are important predictors of disease progression and regression , 2013, European journal of haematology.
[39] G. Verleden,et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors , 2013, Leukemia & lymphoma.
[40] W. Dixon,et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population , 2012, Rheumatology.
[41] A. Loft,et al. Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry , 2012, Annals of the rheumatic diseases.
[42] V. Bojinca,et al. Rheumatic diseases and malignancies. , 2012, Maedica.
[43] A. Sisó-Almirall,et al. [Primary Sjögren syndrome]. , 2012, Praxis.
[44] G. Szücs,et al. Malignancies associated with systemic sclerosis. , 2012, Autoimmunity reviews.
[45] M. Suarez‐Almazor,et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.
[46] T. Barnetche,et al. Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. , 2012, Clinical and experimental rheumatology.
[47] I. Colmegna,et al. Current Understanding of Rheumatoid Arthritis Therapy , 2012, Clinical pharmacology and therapeutics.
[48] A. Sisó-Almirall,et al. Primary Sjögren syndrome , 1986, BMJ : British Medical Journal.
[49] D. Solomon,et al. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. , 2012, Arthritis and rheumatism.
[50] M. Maroun,et al. Serologic laboratory findings in malignancy. , 2011, Rheumatic diseases clinics of North America.
[51] Paul Emery,et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis , 2011, Annals of the rheumatic diseases.
[52] E. Keystone. Does Anti-Tumor Necrosis Factor-α Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm Data , 2011, The Journal of Rheumatology.
[53] H. Amital,et al. Anti-TNF therapy: safety aspects of taking the risk. , 2011, Autoimmunity reviews.
[54] Chun-Ying Wu,et al. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. , 2011, Arthritis and rheumatism.
[55] A. Taniguchi,et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis , 2011, Rheumatology International.
[56] P. Mehta,et al. TNF-α inhibitors : are they carcinogenic ? , 2010 .
[57] A. Gottlieb,et al. Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis , 2010, The Journal of Rheumatology.
[58] H. Sørensen,et al. Systemic sclerosis and the risk of cancer: a nationwide population‐based cohort study , 2010, The British journal of dermatology.
[59] J. Askling,et al. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. , 2010, Arthritis and rheumatism.
[60] L. Kovács,et al. Malignancies in systemic lupus erythematosus. , 2010, Autoimmunity reviews.
[61] G. Burmester,et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT , 2010, Arthritis research & therapy.
[62] N. Harris,et al. Immunomodulator agent-related lymphoproliferative disorders , 2009, Modern Pathology.
[63] S. Bernatsky,et al. Malignancy in systemic lupus erythematosus: what have we learned? , 2009, Best practice & research. Clinical rheumatology.
[64] M. Lebwohl,et al. Treatments for psoriasis and the risk of malignancy. , 2009, Journal of the American Academy of Dermatology.
[65] F. Balkwill. Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.
[66] B. Dijkmans,et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases , 2009, Annals of the rheumatic diseases.
[67] O. Landgren,et al. Autoimmunity and hematologic malignancies: associations and mechanisms , 2009, Leukemia & lymphoma.
[68] D. M. van der Heijde,et al. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.
[69] J. K. Pedersen,et al. Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources , 2009, Rheumatology International.
[70] G. Giles,et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. , 2008, Arthritis and rheumatism.
[71] D. Solomon,et al. The relationship between cancer and rheumatoid arthritis: still a large research agenda , 2008, Arthritis research & therapy.
[72] K. Hemminki,et al. Cancer risk in hospitalized rheumatoid arthritis patients. , 2008, Rheumatology.
[73] M. Hochberg,et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis , 2008, Arthritis research & therapy.
[74] P. Tak,et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.
[75] F. Wolfe,et al. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. , 2007, Arthritis and rheumatism.
[76] A. Ekbom,et al. A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study , 2007, Annals of the rheumatic diseases.
[77] F. Wolfe,et al. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. , 2007, Arthritis and rheumatism.
[78] J. Avorn,et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[79] A. Iliadou,et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[80] N. Hardwick,et al. Multiple haematological malignancies in a patient with rheumatoid arthritis without exposure to disease modifying therapy , 2006, Annals of the rheumatic diseases.
[81] L. Jacobsson,et al. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors , 2005, Annals of the rheumatic diseases.
[82] J. Avorn,et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[83] Theodore R Holford,et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.
[84] W. Miesbach,et al. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies , 2006, Clinical Rheumatology.
[85] E. Zintzaras,et al. The risk of lymphoma development in autoimmune diseases: a meta-analysis. , 2005, Archives of internal medicine.
[86] D. Gladman,et al. Non-Hodgkin’s lymphoma in systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.
[87] A. Tzioufas,et al. Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. , 2005, Autoimmunity reviews.
[88] S. Fischer,et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. , 2004, Journal of the National Cancer Institute.
[89] G. Salles,et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non‐Hodgkin's lymphoma , 2003, British journal of haematology.
[90] L. Klareskog,et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. , 2003, Arthritis and rheumatism.
[91] James M Robins,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[92] D. Isenberg,et al. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. , 2000, Rheumatology.
[93] M. Jewett,et al. Cyclophosphamide-induced bladder cancer. , 1999, The Canadian journal of urology.
[94] D. Knowles. Immunodeficiency-associated lymphoproliferative disorders. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[95] H. Nishimura,et al. Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice. , 1998, Blood.
[96] S. Schwartzman,et al. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. , 1997, Seminars in arthritis and rheumatism.
[97] D. Symmons,et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. , 1996, British journal of rheumatology.
[98] J. Lacy,et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] P. Banks,et al. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. , 1996, Seminars in arthritis and rheumatism.
[100] H. Dombret,et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. , 1995, The Journal of rheumatology.
[101] R. Warnke,et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. , 1993, The New England journal of medicine.
[102] M. Newkirk,et al. Reversible lymphomas. , 1993, The New England journal of medicine.
[103] S. Hirose,et al. Major histocompatibility complex controls clonal proliferation of CD5+ B cells in H‐2‐congenic New Zealand mice: a model for B cell chronic lymphocytic leukemia and autoimmune disease , 1991, European journal of immunology.
[104] C. Werning. [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.
[105] R. Hoover,et al. Increased risk of lymphoma in sicca syndrome. , 1978, Annals of internal medicine.